World's Best Scientists 2026 revealed!
David P. Steensma

David P. Steensma

D-Index & Metrics

Medicine

D-Index
86
Citations
28928
World Ranking
14071
National Ranking
7140

Overview

David P. Steensma is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with a significant body of work in hematology, genetics, public health, environmental and occupational health, oncology, and molecular biology. This broad scope supports investigation into multiple interconnected areas within medical science.

The main topics covered in their publications include:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Cancer Genomics and Diagnostics

Steensma has contributed to various academic venues, with frequent publications appearing in:

  • Mayo Clinic Proceedings
  • Blood
  • Leukemia
  • Blood Advances
  • Journal of Clinical Oncology

Coauthorship is an integral part of their scholarly output. Some of the most frequent collaborators include:

  • Mikkael A. Sekeres
  • Rami S. Komrokji
  • Gail J. Roboz
  • Amy E. DeZern
  • Robert A. Kyle

Among the recent significant publications are:

  • Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms, 2021, Leukemia
  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes, 2021, Journal of Clinical Oncology
  • Bone marrow niches in haematological malignancies, 2020, Nature reviews. Cancer
  • SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS, 2020, Blood
  • Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study, 2020, Blood

Best Publications

  • Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

    David P. Steensma;Rafael Bejar;Siddhartha Jaiswal;R. Coleman Lindsley

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

    R. Coleman Lindsley;Brenton G. Mar;Emanuele Mazzola;Peter V. Grauman

  • Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

    Julia Bohlius;Kurt Schmidlin;Corinne Brillant;Guido Schwarzer

  • The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

    David P. Steensma;David P. Steensma;Gordon W. Dewald;Gordon W. Dewald;Terra L. Lasho;Terra L. Lasho;Heather L. Powell;Heather L. Powell

  • TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

    Rafael Bejar;Allegra Lord;Kristen Stevenson;Michal Bar-Natan

  • Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

    Rafael Bejar;Kristen E. Stevenson;Bennett A. Caughey;Omar Abdel-Wahab

  • Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

    Rafael Bejar;Kristen E. Stevenson;Bennett Caughey;R. Coleman Lindsley

  • Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

    David P. Steensma;Maria R. Baer;James L. Slack;Rena Buckstein

  • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

    Ruben A. Mesa;David P. Steensma;David P. Steensma;Animesh Pardanani;Animesh Pardanani;Chin Yang Li;Chin Yang Li

  • Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

    Ofir Wolach;Ofir Wolach;Ofir Wolach;Rob S. Sellar;Rob S. Sellar;Rob S. Sellar;Kimberly Martinod;Deya Cherpokova

  • Bone marrow niches in haematological malignancies.

    Simón Méndez-Ferrer;Simón Méndez-Ferrer;Simón Méndez-Ferrer;Dominique Bonnet;David P. Steensma;Robert P. Hasserjian

  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

    David A Sallman;Amy E DeZern;Guillermo Garcia-Manero;David P Steensma

  • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

    Elizabeth C. Townsend;Mark A. Murakami;Alexandra Christodoulou;Amanda L. Christie

  • The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

    Ayalew Tefferi;Terra L. Lasho;Susan M. Schwager;David P. Steensma

  • The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

    Ruben A. Mesa;Susan Schwager;Deepti Radia;Andrea Cheville

  • SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

    Mrinal M. Patnaik;Terra L. Lasho;Janice M. Hodnefield;Ryan A. Knudson

  • The Myelodysplastic Syndromes: Diagnosis and Treatment

    David P. Steensma;John M. Bennett

  • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Detlef Haase;Kristen E Stevenson;Donna Neuberg;Jaroslaw P Maciejewski

  • SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Luca Malcovati;Kristen Stevenson;Elli Papaemmanuil;Donna Neuberg

Frequent Co-Authors

Mikkael A. Sekeres
Mikkael A. Sekeres Cleveland Clinic
Richard Stone
Richard Stone Harvard University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Daniel J. DeAngelo
Daniel J. DeAngelo Harvard University
Robert A. Kyle
Robert A. Kyle Mayo Clinic
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Alan F. List
Alan F. List Precision BioSciences
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Donna Neuberg
Donna Neuberg Harvard University
Benjamin L. Ebert
Benjamin L. Ebert Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can greatly expand your career pathways in the healthcare and medical fields. For those interested in healthcare administration, pursuing top online mha programs that are cahme accredited provides a flexible, reputable option to develop leadership skills for management roles.

Registered nurses looking to advance their education may benefit from rn to bsn no clinical hours programs. These online options are ideal for working nurses who need a non-traditional pathway that doesn't require in-person clinical components.

For those seeking to further specialize, doctoral programs in nursing are becoming more accessible. The quickest dnp program options allow experienced nurses to achieve a terminal degree in less time, while the cheapest online dnp programs help reduce the financial barriers often associated with advanced education.

Whether you’re looking to move into healthcare management, advance your clinical nursing career, or pursue doctoral studies, a growing number of online degrees can make your goals more achievable than ever.

Best Scientists Citing David P. Steensma

Trending Scientists